Henry Meds vs IVIM Health
All-in cost at every dose, fee structure, care model, pharmacy disclosure and terms — compared on one basis.
Over a first year at a 2.4 mg maintenance dose, Henry Meds costs about $1,788 against $2,688 — a difference of $900, or roughly 33% of the larger figure.
Both hold one price at every strength, so the ranking does not change with your dose.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
Henry Meds vs IVIM Health at every dose
A single headline figure assumes a maintenance dose neither you nor your prescriber has chosen yet. This is the same comparison at all six strengths.
Henry Meds against IVIM Health at every dose
| Dose | Henry Meds | IVIM Health | Cheaper |
|---|---|---|---|
| 0.25 mg | $149 | $224 | Henry Meds |
| 0.5 mg | $149 | $224 | Henry Meds |
| 1 mg | $149 | $224 | Henry Meds |
| 1.7 mg | $149 | $224 | Henry Meds |
| 2.4 mg | $149 | $224 | Henry Meds |
What differs beyond price
Price is the easiest thing to compare and rarely the thing that decides satisfaction. These are the attributes each programme publishes.
| Attribute | Henry Meds | IVIM Health |
|---|---|---|
| Pricing model | flat at every dose | flat at every dose |
| Membership | none | $75/mo |
| Prepaid rate | none published | none published |
| Visit model | async | video |
| Labs | not required | required |
| Pharmacy disclosure | not named | not named |
| Cancellation | check terms | membership mandatory |
| Regulatory status | compounded, not FDA-approved | compounded, not FDA-approved |
| Evidence status | third-party figure | ✓ verified at source |
Which one, for whom
If you want the lowest total cost: Henry Meds at about $1,788 for a first year.
If you want budget certainty: neither has an advantage — both use the same pricing model.
If you want to verify the supply chain: neither names a dispensing pharmacy in a way we could verify — ask both directly.
If you may need to stop early: compare the cancellation rows above before prepaying. Compounded medication is generally not refundable once it has shipped, so a multi-month term is the wrong structure during titration, when intolerance is the most likely reason to stop.
Switching between them
Usually possible after a clinical review, and the two real risks are a supply gap while a new intake is processed and a new prescriber restarting titration rather than continuing your dose. Confirm dose continuity in writing before cancelling anything, because a month back at 0.25 mg is a month of lost progress no price difference recovers.
If you are already on one of them
Moving from IVIM Health to Henry Meds is worth $900 over a year. Set that against two real switching costs: a gap in supply while a new intake is reviewed, and the possibility that a new prescriber restarts titration rather than continuing your dose. Ask about dose continuation in writing before cancelling anything, because a month back at 0.20.5 mg is a month of lost progress no price difference recovers.
Fee structure, side by side
Henry Meds charges no recurring fee on top of medication. IVIM Health charges a mandatory membership of $75 a month.
This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.
Care model and what it buys
Henry Meds: async, labs not required, none published. IVIM Health: video, labs required, included.
Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.
Verification, which outranks both
Henry Meds: not named. IVIM Health: not named.
A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.
Which is cheaper depends on where you land
A single annual comparison assumes one maintenance dose. This runs both programmes at every plausible outcome, over one year and three.
| If you maintain at | Henry Meds yr 1 | IVIM Health yr 1 | Gap yr 1 | Cheaper | Gap over 3 yrs |
|---|---|---|---|---|---|
| 0.5 mg | $1,788 | $2,688 | $900 | Henry Meds | $2,700 |
| 1 mg | $1,788 | $2,688 | $900 | Henry Meds | $2,700 |
| 1.7 mg | $1,788 | $2,688 | $900 | Henry Meds | $2,700 |
| 2.4 mg | $1,788 | $2,688 | $900 | Henry Meds | $2,700 |
Read the final column before the first. A gap that looks modest over twelve months compounds into the three-year figure, and the withdrawal evidence for this drug class means three years is the more honest planning horizon.
What each one is actually charging for
Henry Meds: $149 medication, no recurring fee. IVIM Health: $149 medication plus $75 platform fee, $900 a year.
Comparing the medication figures alone would make IVIM Health look $75 a month cheaper than it is. That is the single most common distortion in published comparisons of these two.
What $900 a year actually buys
The gap over a first year is $900, about 33% of the larger figure and roughly 6.0 months of therapy at Henry Meds's maintenance rate. Over three years at a stable dose the same difference compounds to about $2,700.
Whether that is decisive depends on what IVIM Health provides that Henry Meds does not. On the published record IVIM Health offers video against async, and its pharmacy disclosure reads not named against not named.
If the difference is nothing you will use, the gap is simply a gap. If it includes clinician access during titration, when dose questions arrive weekly, it may be the better purchase — but that is a judgement about your first three months rather than about the annual total.
How the pricing models interact
Both hold one price across the full 0.25 to 2.4 mg ladder, so this comparison does not move with your dose. Whatever your prescriber decides, Henry Meds stays $75 a month cheaper at every strength.
That makes the decision unusually clean: price is settled, so decide on disclosure, care model and terms. It is also worth noticing because semaglutide titration is slower than most patients expect — four weeks minimum at each step, frequently longer for tolerability — so a dose-scaled programme would have had months to reprice you.
The fee structures are not the same purchase
Henry Meds charges no separate recurring fee; IVIM Health bills $75.
Over three years that difference alone is $2,700, and it is the component most likely to be missing from any comparison you read elsewhere. Published tables tend to compare medication prices rather than totals, which flatters whichever programme charges the larger fee.
A membership earns its cost when you use it. During titration, unlimited clinician messaging is genuinely valuable — semaglutide's gastrointestinal effects cluster in the first weeks after each step up. At stable maintenance it is close to idle. Ask what happens to your prescription if the membership lapses mid-supply.
Committing to a term changes the answer, and the risk
Henry Meds publishes no prepaid rate; IVIM Health publishes none.
Prepaying lowers the rate and makes the money effectively unrecoverable, because compounded medication is generally not refundable once shipped. Entering a term during titration commits cash against the most likely reason to stop, which is not tolerating the drug.
The sequencing that protects you: monthly billing until you have held a maintenance dose for a full cycle, then a term once the main reason to stop has passed. Two questions first, both answerable in writing — does the rate hold for the whole term, and what happens if a clinician stops your prescription mid-term.
One of these figures is better evidenced than the other
IVIM Health's price was read on its own published material and dated. Henry Meds's comes from a third-party source we have not confirmed, and is labelled as such everywhere it appears.
That asymmetry matters more than a modest price difference. Where we have been able to check an unconfirmed figure against a provider's own page, the number usually moved upward: promotional first months, prepaid rates quoted as monthly, and medication-only figures excluding a mandatory membership all push the same way.
Treat Henry Meds's figure as indicative and confirm it at checkout before letting it decide anything.
Moving from IVIM Health to Henry Meds, and what it costs
The arithmetic is $900 over a year. Two things eat it: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.
The second is expensive. Semaglutide titration runs at least sixteen weeks from 0.25 mg to 2.4 mg when every step goes smoothly, so a restart can cost a third of a year. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.
Take three things with you: your current dose and the date you reached it, the concentration printed on your current vial, and any record of adverse effects with dates. Concentrations are not standardised between compounders, and carrying instructions from an old vial to a new one is a real hazard rather than a theoretical one.
What neither table can tell you
Whether shipments arrive on time, how fast a clinician replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. Those decide satisfaction more than price does.
We hold no measurements of any of them we would defend, so they appear nowhere in our tables rather than being estimated into a score. The usable proxy is what each programme publishes before it has your money — and Henry Meds and IVIM Health can be judged on that today.
Re-run this at your actual maintenance dose annually. Programmes do not notify existing patients when a competitor drops below them, and semaglutide pricing moved repeatedly through 2025 and 2026.
If your titration runs slower than the schedule
The approved ladder moves every four weeks, and a large share of patients hold at a step longer because of nausea or reflux. Add two extra months before maintenance and Henry Meds costs $298 more that year against $448 at IVIM Health.
On flat pricing an extra month costs the maintenance rate regardless of the dose delivered, which is the one scenario where flat pricing works against you. On dose-scaled pricing it costs less but reproduces a step you had already paid for.
Neither is a reason to choose differently alone. It is a reason to run both one step slower than you expect and take the higher figure into the decision.
The three-year exposure
At maintenance the annual difference is $900 and over three years $2,700. Three years is the honest horizon rather than a rhetorical one: the withdrawal evidence for this drug class shows substantial regain after stopping.
The realistic question is not what a year costs but whether you can sustain the programme indefinitely. A programme abandoned for cost in month fourteen has cost more than the dearer one you would have kept, because the interruption undoes the result the spending bought.
The decision from Henry Meds's side
You would choose Henry Meds if its structure matches your expected course: flat pricing suits an uncertain or escalating titration, no recurring platform fee keeps the advertised figure honest, and its entry price of $149 sets your first month.
You would not choose it if the opposite is true of your course, or if the disclosure rows leave a question you cannot get answered in writing.
The decision from IVIM Health's side
You would choose IVIM Health if its flat rate protects you against a dose increase you cannot predict, and if paying $75 a month for platform access is something you will actually use. Its first month costs $224 and its maintenance rate is $224.
You would not choose it if the $900 first-year gap is decisive for your budget and nothing in its disclosure justifies the difference.
Where henry meds and ivim health sits in the sequence
Order matters more than most guidance admits. Establish coverage first, because a covered prescription under a documented indication beats every cash route here. Then establish the dose you expect to hold. Only then compare prices.
Most people do this backwards — compare prices, enrol, then discover an indication they already qualified for. Semaglutide has more of those routes than most weight-management drugs: type 2 diabetes, cardiovascular risk reduction, and a liver indication for a narrow population.
The check that costs nothing
Ask which pharmacy fills the prescription and search your state board's licensee register for it. Two minutes, free, and possible for only 6 of the 20 priced programmes because the rest do not name one.
A name and a licence number is the good answer. A category is incomplete but honest. A deflection about proprietary partnerships is the answer.
Why this matters more here than for approved medicines
An approved product has been reviewed before marketing and is made under a federal quality system with supply-chain traceability. A compounded preparation has not been through that review. Its assurance comes from the pharmacy, the state board licensing it, and at good operations batch testing for sterility and potency.
That is a legitimate framework rather than a loophole, and it moves verification work onto you. It is the honest reason the compounded price is lower.
Reading this alongside the rest of the site
Pricing pages isolate one component. Provider reviews carry the whole record for one programme. Comparisons run two side by side at every dose. The rankings sort the same dataset on different questions. None is the whole picture and none is meant to be.
If you read one other page, make it how to verify a pharmacy. Price is the easiest thing to compare and rarely the thing that goes wrong.
What we would need to change our mind
A programme publishing a figure at a dose tier currently blank. A named dispensing pharmacy with a checkable licence. A pricing model changing in either direction. A regulatory action. Or a correction from a reader with a source we can open.
All five are logged with the date they landed, on the change log and in the dataset. Prices here were captured 2026-08-05.
What this site will not do
Publish an estimated price for a programme that does not publish one. Rank a programme higher because it pays. Present a compounded preparation as equivalent to an approved product. Or carry a figure without the date it was captured.
Those four rules cost us pages, rankings and revenue, and they are the only reason a reader has to prefer this to a round-up assembled in an afternoon. A price without its date is not a fact, and a comparison built from undated prices is not a comparison.
Who this site is not for
Anyone with coverage under a documented indication, who should use it rather than read a cash comparison. Anyone looking for a source without a prescription, which this site will not help with. And anyone wanting a single confident recommendation, because the honest answer depends on your dose, your coverage and your tolerance for commitment.
If you want the short version anyway: price the dose you will hold, add every fee, verify the pharmacy, and avoid long prepaid terms until you have tolerated a maintenance dose for a cycle.
Where the money actually separates
A single annual figure hides when the gap opens. Tracked month by month through a first year you can see whether the difference is front-loaded during titration or accumulates quietly at maintenance.
| By end of | Henry Meds | IVIM Health | Gap |
|---|---|---|---|
| Month 1 | $149 | $224 | $75 |
| Month 2 | $298 | $448 | $150 |
| Month 3 | $447 | $672 | $225 |
| Month 6 | $894 | $1,344 | $450 |
| Month 9 | $1,341 | $2,016 | $675 |
| Month 12 | $1,788 | $2,688 | $900 |
Across the year the gap reaches $900, roughly 33% of the larger total and about 6.0 months of therapy at Henry Meds's maintenance rate. Over three years at a stable dose the same difference compounds to roughly $2,700.
Does the answer change with your dose?
Henry Meds is cheaper at every strength, so this comparison does not turn on where you settle. The decision moves to what else differs: disclosure, care model, commitment terms and behaviour when a shipment fails.
Commitment and what each puts at risk
Henry Meds publishes no prepaid term. IVIM Health publishes no prepaid term.
Prepaying lowers the rate and makes the money effectively unrecoverable, because compounded medication is generally not refundable once shipped. During titration that is the wrong structure: it commits against the most likely reason to stop. After a stable cycle at maintenance it is reasonable.
Care model and what you can verify
Henry Meds: async, labs not required, pharmacy not named, cancellation check terms.
IVIM Health: video, labs required, pharmacy not named, cancellation membership mandatory.
Where one names a pharmacy and the other does not, that difference outranks a modest price gap. It is the only disclosure that lets you check a public register before injecting something weekly, and it costs a programme nothing to publish.
If you are already on one of them
Moving from IVIM Health to Henry Meds is worth $900 over a year, about 6.0 months of therapy at the cheaper rate. Set that against two real switching costs: a supply gap while an intake is reviewed, and the possibility that a new prescriber restarts titration.
Ask about dose continuation in writing before cancelling anything. A month back at 0.20.5 mg is a month of lost progress that no price difference recovers, and it is the most common regret reported by people who switched for a small saving.
What neither table can tell you
Shipping reliability, how fast a clinician actually replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. Those decide satisfaction more than price does, and we hold no measurements of them we would defend, so they are absent rather than estimated.
The one usable proxy is what each programme publishes before it has your money. A programme that states its price at every dose, names its pharmacy and puts cancellation terms in writing has already told you something about how it behaves when there is a problem.
Running this comparison again later
Both figures carry a capture date and both will change. Programmes do not notify existing patients when a competitor drops below them, and several tracked programmes moved pricing more than once in the past year.
Re-run this at your actual maintenance dose annually, and treat any figure older than a month as needing a re-check before you act on it.
Where both of these sit in the wider market
Henry Meds at $1,788 and IVIM Health at $2,688 for a first year sit against a market running from $1,740 to $3,625. At least one of them sits above the midpoint of what we track, which is worth knowing before treating this pairing as a shortlist.
If neither is close to the cheapest tracked route, the useful question is not which of these two wins but why you are choosing between these two at all. The comparison matrix will show what else is available at your dose in about ten seconds.
If you are already on one of them
Moving from IVIM Health to Henry Meds is worth $900 over a year. Set that against two real switching costs: a gap in supply while a new intake is reviewed, and the possibility that a new prescriber restarts titration rather than continuing your dose. Ask about dose continuation in writing before cancelling anything, because a month back at 0.20.5 mg is a month of lost progress no price difference recovers.
Fee structure, side by side
Henry Meds charges no recurring fee on top of medication. IVIM Health charges a mandatory membership of $75 a month.
This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.
Care model and what it buys
Henry Meds: async, labs not required, none published. IVIM Health: video, labs required, included.
Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.
Verification, which outranks both
Henry Meds: not named. IVIM Health: not named.
A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.
Which is cheaper depends on where you land
A single annual comparison assumes one maintenance dose. This runs both programmes at every plausible outcome, over one year and three.
| If you maintain at | Henry Meds yr 1 | IVIM Health yr 1 | Gap yr 1 | Cheaper | Gap over 3 yrs |
|---|---|---|---|---|---|
| 0.5 mg | $1,788 | $2,688 | $900 | Henry Meds | $2,700 |
| 1 mg | $1,788 | $2,688 | $900 | Henry Meds | $2,700 |
| 1.7 mg | $1,788 | $2,688 | $900 | Henry Meds | $2,700 |
| 2.4 mg | $1,788 | $2,688 | $900 | Henry Meds | $2,700 |
Read the final column before the first. A gap that looks modest over twelve months compounds into the three-year figure, and the withdrawal evidence for this drug class means three years is the more honest planning horizon.
What each one is actually charging for
Henry Meds: $149 medication, no recurring fee. IVIM Health: $149 medication plus $75 platform fee, $900 a year.
Comparing the medication figures alone would make IVIM Health look $75 a month cheaper than it is. That is the single most common distortion in published comparisons of these two.
What $900 a year actually buys
The gap over a first year is $900, about 33% of the larger figure and roughly 6.0 months of therapy at Henry Meds's maintenance rate. Over three years at a stable dose the same difference compounds to about $2,700.
Whether that is decisive depends on what IVIM Health provides that Henry Meds does not. On the published record IVIM Health offers video against async, and its pharmacy disclosure reads not named against not named.
If the difference is nothing you will use, the gap is simply a gap. If it includes clinician access during titration, when dose questions arrive weekly, it may be the better purchase — but that is a judgement about your first three months rather than about the annual total.
How the pricing models interact
Both hold one price across the full 0.25 to 2.4 mg ladder, so this comparison does not move with your dose. Whatever your prescriber decides, Henry Meds stays $75 a month cheaper at every strength.
That makes the decision unusually clean: price is settled, so decide on disclosure, care model and terms. It is also worth noticing because semaglutide titration is slower than most patients expect — four weeks minimum at each step, frequently longer for tolerability — so a dose-scaled programme would have had months to reprice you.
The fee structures are not the same purchase
Henry Meds charges no separate recurring fee; IVIM Health bills $75.
Over three years that difference alone is $2,700, and it is the component most likely to be missing from any comparison you read elsewhere. Published tables tend to compare medication prices rather than totals, which flatters whichever programme charges the larger fee.
A membership earns its cost when you use it. During titration, unlimited clinician messaging is genuinely valuable — semaglutide's gastrointestinal effects cluster in the first weeks after each step up. At stable maintenance it is close to idle. Ask what happens to your prescription if the membership lapses mid-supply.
Committing to a term changes the answer, and the risk
Henry Meds publishes no prepaid rate; IVIM Health publishes none.
Prepaying lowers the rate and makes the money effectively unrecoverable, because compounded medication is generally not refundable once shipped. Entering a term during titration commits cash against the most likely reason to stop, which is not tolerating the drug.
The sequencing that protects you: monthly billing until you have held a maintenance dose for a full cycle, then a term once the main reason to stop has passed. Two questions first, both answerable in writing — does the rate hold for the whole term, and what happens if a clinician stops your prescription mid-term.
One of these figures is better evidenced than the other
IVIM Health's price was read on its own published material and dated. Henry Meds's comes from a third-party source we have not confirmed, and is labelled as such everywhere it appears.
That asymmetry matters more than a modest price difference. Where we have been able to check an unconfirmed figure against a provider's own page, the number usually moved upward: promotional first months, prepaid rates quoted as monthly, and medication-only figures excluding a mandatory membership all push the same way.
Treat Henry Meds's figure as indicative and confirm it at checkout before letting it decide anything.
Moving from IVIM Health to Henry Meds, and what it costs
The arithmetic is $900 over a year. Two things eat it: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.
The second is expensive. Semaglutide titration runs at least sixteen weeks from 0.25 mg to 2.4 mg when every step goes smoothly, so a restart can cost a third of a year. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.
Take three things with you: your current dose and the date you reached it, the concentration printed on your current vial, and any record of adverse effects with dates. Concentrations are not standardised between compounders, and carrying instructions from an old vial to a new one is a real hazard rather than a theoretical one.
What neither table can tell you
Whether shipments arrive on time, how fast a clinician replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. Those decide satisfaction more than price does.
We hold no measurements of any of them we would defend, so they appear nowhere in our tables rather than being estimated into a score. The usable proxy is what each programme publishes before it has your money — and Henry Meds and IVIM Health can be judged on that today.
Re-run this at your actual maintenance dose annually. Programmes do not notify existing patients when a competitor drops below them, and semaglutide pricing moved repeatedly through 2025 and 2026.
If your titration runs slower than the schedule
The approved ladder moves every four weeks, and a large share of patients hold at a step longer because of nausea or reflux. Add two extra months before maintenance and Henry Meds costs $298 more that year against $448 at IVIM Health.
On flat pricing an extra month costs the maintenance rate regardless of the dose delivered, which is the one scenario where flat pricing works against you. On dose-scaled pricing it costs less but reproduces a step you had already paid for.
Neither is a reason to choose differently alone. It is a reason to run both one step slower than you expect and take the higher figure into the decision.
The three-year exposure
At maintenance the annual difference is $900 and over three years $2,700. Three years is the honest horizon rather than a rhetorical one: the withdrawal evidence for this drug class shows substantial regain after stopping.
The realistic question is not what a year costs but whether you can sustain the programme indefinitely. A programme abandoned for cost in month fourteen has cost more than the dearer one you would have kept, because the interruption undoes the result the spending bought.
The decision from Henry Meds's side
You would choose Henry Meds if its structure matches your expected course: flat pricing suits an uncertain or escalating titration, no recurring platform fee keeps the advertised figure honest, and its entry price of $149 sets your first month.
You would not choose it if the opposite is true of your course, or if the disclosure rows leave a question you cannot get answered in writing.
The decision from IVIM Health's side
You would choose IVIM Health if its flat rate protects you against a dose increase you cannot predict, and if paying $75 a month for platform access is something you will actually use. Its first month costs $224 and its maintenance rate is $224.
You would not choose it if the $900 first-year gap is decisive for your budget and nothing in its disclosure justifies the difference.
Where henry meds and ivim health sits in the sequence
Order matters more than most guidance admits. Establish coverage first, because a covered prescription under a documented indication beats every cash route here. Then establish the dose you expect to hold. Only then compare prices.
Most people do this backwards — compare prices, enrol, then discover an indication they already qualified for. Semaglutide has more of those routes than most weight-management drugs: type 2 diabetes, cardiovascular risk reduction, and a liver indication for a narrow population.
The check that costs nothing
Ask which pharmacy fills the prescription and search your state board's licensee register for it. Two minutes, free, and possible for only 6 of the 20 priced programmes because the rest do not name one.
A name and a licence number is the good answer. A category is incomplete but honest. A deflection about proprietary partnerships is the answer.
Why this matters more here than for approved medicines
An approved product has been reviewed before marketing and is made under a federal quality system with supply-chain traceability. A compounded preparation has not been through that review. Its assurance comes from the pharmacy, the state board licensing it, and at good operations batch testing for sterility and potency.
That is a legitimate framework rather than a loophole, and it moves verification work onto you. It is the honest reason the compounded price is lower.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.
Common questions
Is Henry Meds or IVIM Health cheaper?
Henry Meds is cheaper, at about $1,788 for a first year against $2,688 — a difference of $900.
Do Henry Meds and IVIM Health charge a membership on top of medication?
Henry Meds: no. IVIM Health: yes, $75 a month. Every figure on this page includes it where charged.
Does Henry Meds or IVIM Health name its dispensing pharmacy?
Henry Meds: not named. IVIM Health: not named. It is the disclosure that lets you check a state board register before you inject anything weekly.
Can I switch between them mid-treatment?
Usually yes, after a clinical review. Confirm dose continuity in writing and do not cancel the old programme until the new one has shipped, because a supply gap costs more than a price difference.
Is either Henry Meds or IVIM Health FDA-approved?
Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. Where a programme supplies brand product, that product is approved; the programme around it is not a regulated entity in the same sense.